Naxitamab (Ganglioside GD2) Antibody, Monoclonal
| Code | Size | Price |
|---|
| PSI-10-932-0.1mg | 0.1mg | £657.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Isotype: IgG1-kappa
Antibody Clonality: Recombinant Antibody
Regulatory Status: RUO
Shipping:
blue ice
Storage:
Store at -80˚C
Documents
Further Information
Additional Names:
Hu3F8
Background:
Naxitamab is humanized monoclonal antibody that targets GD2 antigen. GD2 antigen is expressed on the surface of tumors generated by neuroectoderm, including tumors such as neuroblastoma, melanoma, and osteosarcoma. Naxitamab can trigger antibody-mediated cytotoxicity and activate the complement system in the immune system by binding to the GD2 antigen on the surface of the tumor, thereby achieving the effect of killing the tumor.
Buffer:
PBS buffer pH7.5
Concentration:
batch dependent
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Chimeric / Ganglioside GD2 [Homo sapiens]
NCBI Organism:
homo sapiens
Purification:
>95%
Research Area:
Drug Analogues
Source:
CHO cells
User NOte:
Optimal dilutions for each application to be determined by the researcher.